Lindbrook Capital, LLC Cellectis S.A. Transaction History

Lindbrook Capital, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 21, 2022	SELL	$3.45 - $8.77 $5,275 - $13,409	-1,529 Closed	0 $0
Q4 2021 Jan 18, 2022	BUY	$8.01 - $12.84 $8,538 - $13,687	1,066 Added 230.24%	1,529 $12,000
Q3 2021 Nov 05, 2021	BUY	$11.94 - $16.09 $3,498 - $4,714	293 Added 172.35%	463 $6,000
Q2 2021 Jul 27, 2021	SELL	$14.36 - $20.93 $890 - $1,297	-62 Reduced 26.72%	170 $3,000
Q3 2020 Nov 03, 2020	SELL	$15.7 - $20.84 $1,946 - $2,584	-124 Reduced 34.83%	232 $4,000
Q2 2020 Jul 27, 2020	BUY	$8.21 - $21.02 $2,027 - $5,191	247 Added 226.61%	356 $6,000
Q1 2020 Apr 22, 2020	SELL	$7.81 - $18.82 $14,831 - $35,739	-1,899 Reduced 94.57%	109 $1,000
Q4 2019 Jan 27, 2020	BUY	$9.73 - $19.31 $12,152 - $24,118	1,249 Added 164.56%	2,008 $34,000
Q3 2019 Oct 31, 2019	BUY	$10.15 - $16.89 $3,948 - $6,570	389 Added 105.14%	759 $8,000
Q2 2019 Jul 24, 2019	BUY	$14.6 - $20.6 $5,402 - $7,622	370 New	370 $5,000
Q1 2019 Apr 23, 2019	SELL	$15.53 - $19.75 $2,609 - $3,318	-168 Closed	0 $0
Q4 2018 Feb 07, 2019	BUY	$15.58 - $28.41 $2,617 - $4,772	168 New	168 $2,000

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.